Q10109 (Q10109): Difference between revisions
Jump to navigation
Jump to search
(Removed claims) |
(Changed an Item) |
||||||||||||||
| Property / EU contribution | |||||||||||||||
10,847,356.92 Czech koruna
| |||||||||||||||
| Property / EU contribution: 10,847,356.92 Czech koruna / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / EU contribution | |||||||||||||||
433,894.2768 Euro
| |||||||||||||||
| Property / EU contribution: 433,894.2768 Euro / rank | |||||||||||||||
Preferred rank | |||||||||||||||
| Property / EU contribution: 433,894.2768 Euro / qualifier | |||||||||||||||
exchange rate to Euro: 0.04 Euro
| |||||||||||||||
| Property / EU contribution: 433,894.2768 Euro / qualifier | |||||||||||||||
point in time: 10 January 2020
| |||||||||||||||
| Property / budget | |||||||||||||||
18,868,250.0 Czech koruna
| |||||||||||||||
| Property / budget: 18,868,250.0 Czech koruna / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / budget | |||||||||||||||
754,730.0 Euro
| |||||||||||||||
| Property / budget: 754,730.0 Euro / rank | |||||||||||||||
Preferred rank | |||||||||||||||
| Property / budget: 754,730.0 Euro / qualifier | |||||||||||||||
exchange rate to Euro: 0.04 Euro
| |||||||||||||||
| Property / budget: 754,730.0 Euro / qualifier | |||||||||||||||
point in time: 10 January 2020
| |||||||||||||||
Revision as of 16:25, 11 February 2020
Project in Czech Republic financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project in Czech Republic financed by DG Regio |
Statements
10,847,356.92 Czech koruna
0 references
18,868,250.0 Czech koruna
0 references
57.4899999735005 percent
0 references
1 January 2016
0 references
28 September 2019
0 references
ELISABETH PHARMACON, spol. s r.o.
0 references
49°11'55.75"N, 16°38'29.22"E
0 references
61500
0 references
Projekt se zaměřuje na výzkum v nové oblasti DNA technologií s velkým potenciálem budoucího využití v klinické praxi pro zlepšení diagnostiky civilizačních chorob. Cílem projektu je výzkum klinicky významných miRNA molekul a jejich detekce a příprava dvou prototypů souprav pro sekvenování nové generace určených pro diagnostiku cystické fibrózy a rakoviny prsu a vaječníků. Výstupem projektu budou dva prototypy, na které bude možné navázat vývoj komerčních diagnostických souprav. a. (Czech)
0 references
Identifiers
CZ.01.1.02/0.0/0.0/15_018/0004701
0 references